Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 328 (Siltuximab) in Metastatic Renal Cell Carcinoma
NCT00265135Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2003
- Primary completion
- Feb 2006
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of siltuximab in renal cell carcinoma (RCC), sponsored by Janssen Pharmaceutical. Started Aug 2003; status: completed.
02
Drugs
siltuximab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00265135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265135.